Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...
Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...
Johnson & Johnson is suing Samsung Bioepis for allegedly breaching the terms of a contract regarding the launch of the Korean ...
Johnson & Johnson filed a lawsuit against Samsung Bioepis for allegedly breaching their agreement over the launch of ...
Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...
Pharmalittle: We’re reading about Zepbound price and dose changes, compounders suing FDA, and more
Eli Lilly will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback